Familial multiple fibrofolliculoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:338
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Familial multiple fibrofolliculoma, also known as Birt-Hogg-Dubé syndrome (BHD), is a rare inherited condition that mainly affects the skin, kidneys, and lungs. It is caused by changes (mutations) in a gene called FLCN, which normally helps control cell growth. When this gene does not work properly, certain types of benign (non-cancerous) skin growths can develop, along with an increased risk of kidney tumors and lung cysts. The most visible signs of this condition are small, smooth, flesh-colored bumps on the face, neck, and upper body. These bumps are called fibrofolliculomas, trichodiscomas, and acrochordons (skin tags). They usually appear in adulthood and are not painful, but they can be a cosmetic concern. People with this condition also have a higher-than-average chance of developing cysts in the lungs, which can sometimes cause a collapsed lung (pneumothorax). Kidney tumors — both benign and cancerous — can also occur and need regular monitoring. There is no cure for Birt-Hogg-Dubé syndrome, but the condition can be managed effectively with regular check-ups, skin treatments for cosmetic concerns, and surveillance imaging to catch kidney or lung problems early. With proper monitoring, many people with this condition live full and healthy lives.

Key symptoms:

Small, smooth, flesh-colored bumps on the face and neck (fibrofolliculomas)Skin tags (acrochordons), especially on the neck and armpitsLung cysts (air-filled pockets in the lungs)Collapsed lung (pneumothorax), sometimes recurringKidney tumors (can be benign or cancerous)Multiple small white bumps on the upper body (trichodiscomas)Shortness of breath if a lung cyst rupturesChest pain from a collapsed lung

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Familial multiple fibrofolliculoma.

View clinical trials →

No actively recruiting trials found for Familial multiple fibrofolliculoma at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Familial multiple fibrofolliculoma community →

No specialists are currently listed for Familial multiple fibrofolliculoma.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Familial multiple fibrofolliculoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Familial multiple fibrofolliculomaForum →

No community posts yet. Be the first to share your experience with Familial multiple fibrofolliculoma.

Start the conversation →

Latest news about Familial multiple fibrofolliculoma

No recent news articles for Familial multiple fibrofolliculoma.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How often should I have imaging of my kidneys and lungs, and what type of scan is best for me?,Should my children and siblings be tested for the FLCN gene mutation?,What activities should I avoid to reduce my risk of a collapsed lung?,Are there any clinical trials or new treatments I should know about?,What are the warning signs that a kidney tumor needs treatment rather than just monitoring?,Can the skin growths be treated, and will they come back after treatment?,Who else should be part of my care team, and how often should I see each specialist?

Common questions about Familial multiple fibrofolliculoma

What is Familial multiple fibrofolliculoma?

Familial multiple fibrofolliculoma, also known as Birt-Hogg-Dubé syndrome (BHD), is a rare inherited condition that mainly affects the skin, kidneys, and lungs. It is caused by changes (mutations) in a gene called FLCN, which normally helps control cell growth. When this gene does not work properly, certain types of benign (non-cancerous) skin growths can develop, along with an increased risk of kidney tumors and lung cysts. The most visible signs of this condition are small, smooth, flesh-colored bumps on the face, neck, and upper body. These bumps are called fibrofolliculomas, trichodiscoma

How is Familial multiple fibrofolliculoma inherited?

Familial multiple fibrofolliculoma follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Familial multiple fibrofolliculoma typically begin?

Typical onset of Familial multiple fibrofolliculoma is adult. Age of onset can vary across affected individuals.